Given Imaging has reported positive data from a prospective, blinded, multicentre study that investigated the sensitivity of PillCam Colon 2 video capsule for detecting clinically relevant polypoid lesions.

The capsule is designed to be ingested by the patient. It is fitted with two miniature colour video cameras (one on each end), a battery and an LED light source.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The study enrolled 117 patients and confirmed that the second-generation PillCam Colon capsule demonstrated sensitivity and specificity for detecting polyps greater than or equal to 6 mm and greater than or equal to 10mm.

It also found that per-patient colon capsule endoscopy sensitivity for polyps greater than or equal to 6 mm and greater than or equal to 10mm was 84% and 88%, with specificities of 64% and 95%, respectively.

In addition, colon capsule endoscopy also detected all three invasive carcinomas.

Professor Cristiano Spada of Catholic University in Rome, Italy, said that colon capsule endoscopy is a patient-friendly, minimally invasive technology that enables visualisation of the colon without sedation or air insufflation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"The high sensitivity for clinically relevant lesions shown in the study demonstrates the value of this tool to complement colonoscopy, which may ultimately result in improved patient compliance with colorectal screening guidelines,” Spada added.

The company has initiated a multicentre pivotal study for PillCam Colon 2, which will support the company’s planned 510(k) submission to the US Food and Drug Administration.